Brief: Calidi Biotherapeutics And City Of Hope Announce Funding To Advance Cld-101 In Ovarian Cancer
11/03/2024 11:49
March 11 (Reuters) - Calidi Biotherapeutics Inc
CLDI.A :
* CALIDI BIOTHERAPEUTICS AND CITY OF HOPE ANNOUNCE FUNDING
FROM
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE (CIRM) TO ADVANCE
CLD-101 (NEURONOVA) IN OVARIAN CANCER
Source text for Eikon: ID:nBw8zd0F3a
Further company coverage: CLDI.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma